fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

ACC 2024: Investigative olezarsen significantly lowers high triglycerides

Written by | 20 Apr 2024

Investigative olezarsen lowers triglyceride levels by about half at 6 months without noteworthy adverse effects, researchers from the BRIDGE-TIMI 73a trial reported on April 7, 2024 at the… read more.

ACC 2024 Preventive PCI for High-Risk Plaques Reduces Cardiac Events

Written by | 19 Apr 2024

When compared with similar patients who were only treated with drugs, patients with vulnerable atherosclerotic plaques in the arteries of their hearts have achieved a significantly reduced relative… read more.

ACC 2024: Adding investigative lerodalcibep to cholesterol lowering treatment shows significant efficacy

Written by | 18 Apr 2024

By adding investigational lerodalcibep to their standard cholesterol-lowering treatment for a year, patients at high risk for a heart attack or stroke achieved a reduction of “bad” cholesterol… read more.

ACC 2024 – Plozasiran effective for severe hypertriglyceridemia in patients at high risk of pancreatitis

Written by | 12 Apr 2024

Patients with severely elevated triglyceride levels who are therefore at risk of developing acute pancreatitis have achieved a 74% average reduction in triglyceride levels, when treated for 24… read more.

ACC 2024: Acute coronary syndromes patients stop aspirin safely a month after PCI

Written by | 11 Apr 2024

The majority of patients diagnosed with ACS/Acute Coronary Syndromes, including heart attacks and chest pain caused by decreased blood flow to the heart, appear to be able to… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.